Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

Abstract Introduction The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinical outcomes. However, mAbs, such as rituximab, natalizumab, and ocrel...

Full description

Bibliographic Details
Main Authors: Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi, Yazed AlRuthia
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Health Services Research
Subjects:
Multiple sclerosis
Relapsing-remitting
Natalizumab
Rituximab
Ocrelizumab
Cost effectiveness
Online Access:https://doi.org/10.1186/s12913-023-09462-z

Internet

https://doi.org/10.1186/s12913-023-09462-z

Similar Items